New-treatments-for-ankylosing-spondylitis

New Treatment Approved for Ankylosing Spondylitis: FDA OKs

Spondylitis.orgDec 17, 2021 · 12/17/2021. The U.S. FDA has approved a new medication to treat ankylosing spondylitis (AS) – tofacitinib, known as Xeljanz or Xeljanz XR. Tofacitinib is the first Janus kinase (JAK) inhibitor, or JAKi, to receive approval to treat adults with active AS.

https://spondylitis.org/research-new/new-treatment-approved-for-ankylosing-spondylitis-fda-oks-first-jak-inhibitor/ 

Medical Treatment of Ankylosing Spondylitis

Ncbi.nlm.nih.govSep 29, 2014 · 1. Diagnostic Criteria for ASsessment of Ankylosing Spondylitis (ASAS) 6) Due to the limitations of conventional modified New York criteria and the need for early detection and diagnosis, a wider term, axial spondyloarthritis, is now used instead of ankylosing spondylitis so that early diagnosis can be made if there are clinical symptoms and MRI findings but no …

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971137/ 

New Targeted Treatment for Ankylosing Spondylitis

Academic.oup.comApr 01, 2016 · Neurosurgeons are familiar with ankylosing spondylitis (AS) as a chronic, immune-mediated disease characterized by inflammation and new bone formation in the axial spine, resulting in autofusion of the spinal column susceptible to Chance fractures. 1 Patients with AS are more familiar with the considerable pain and the poor quality of life that results from …

https://academic.oup.com/neurosurgery/article/78/4/N14/2453582 

New Drugs for Ankylosing Spondylitis Treatment Coming …

Globenewswire.comApr 16, 2021 · Los Angeles, USA, April 15, 2021 (GLOBE NEWSWIRE) -- New Drugs for Ankylosing Spondylitis Treatment Coming Down the Pipeline: An Updated Clinical Status by DelveInsight Around 30+ notable

https://www.globenewswire.com/news-release/2021/04/16/2211341/0/en/New-Drugs-for-Ankylosing-Spondylitis-Treatment-Coming-Down-the-Pipeline-An-Updated-Clinical-Status-by-DelveInsight.html 

New treatment options in ankylosing spondylitis: a role

Ard.bmj.comThe spondyloarthropathies (SpA) comprise ankylosing spondylitis (AS), reactive arthritis, some forms of psoriatic arthritis/spondylitis, arthritis/spondylitis associated with inflammatory bowel disease, and undifferentiated SpA. AS is the most common subgroup with the most severe course of the disease. In two studies from Germany, one performed among blood donors and one in …

https://ard.bmj.com/content/60/suppl_3/iii58 

JAK Inhibitors Offer New Hope for Treating Ankylosing

Spineuniverse.comPeople with ankylosing spondylitis may soon have new treatment options. The disease most often starts with pain and stiffness in the back, usually after a period of inactivity. The symptoms start before age 45 and gradually develop. There is no cure for AS, but there are treatments that can improve symptoms dramatically and even put AS into

https://www.spineuniverse.com/conditions/spinal-arthritis/jak-inhibitors-ankylosing-spondylitis 

Recent advances in ankylosing spondylitis: understanding

Ncbi.nlm.nih.govSep 21, 2018 · Genetics. AS is considered an inherited disease, as over 90% of the risk for its development relies on genes 2.However, the HLA-B27 allele accounts for only 20% of the genetic effect 1.Other alleles, especially HLA-B, are thought to play an important role in the disease: HLA-B*13:02, HLA-B*40:01, HLA-B*47, and HLA-B*51 are some examples 3.The most significant …

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173104/ 

New guidelines for treatment of ankylosing spondylitis

Link.springer.comFeb 27, 2016 · New guidelines on the treatment of ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA), developed by the American College of Rheumatology, Spondylitis Association of America, and Spondyloarthritis Research and Treatment Network, have been published in Arthritis Care & Research.

https://link.springer.com/article/10.1007/s40274-016-2819-5